The release and absorption profile of an oral medication is influenced by the
physicochemical properties of the drug and its formulation, as well as by the anatomy and …

The newest class of antiretrovirals for all persons living with HIV are the integrase strand
transfer inhibitors (INSTIs). Since 2007, five INSTIs have been introduced: raltegravir …

Purpose of review The goal of this paper is to provide an up-to-date review of adverse
events related to the class of integrase strand transfer inhibitors (INSTIs), which became the …

Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of
HIV-1 infection brings promise of a new mode of delivery and potential solutions to some …

An estimated 1.3 million pregnant women were living with HIV in 2018. HIV infection is
associated with adverse pregnancy outcomes and all HIV-positive pregnant women …

Abstract Bictegravir, cabotegravir, dolutegravir, elvitegravir, and raltegravir are members of
the latest class of antiretrovirals available to treat human immunodeficiency virus (HIV) …

Children born to mothers, with or at risk, of human immunodeficiency virus type-1 (HIV-1)
infection are on the rise due to affordable access of antiretroviral therapy (ART) to pregnant …

In 1989, one in four (25%) infants born to women living with HIV were infected; by the age of
2 years, there was 25% mortality among them due to HIV. These and other pieces of data …

Human T-cell lymphotropic virus type 1 (HTLV-1) is a deltaretrovirus most prevalent in
southwestern Japan, sub-Saharan Africa, Australia, South America, and the Caribbean …

More than 10 million people worldwide are infected with the retrovirus human T-cell
lymphotropic virus type 1 (HTLV-1). Infection phenotypes can range from asymptomatic to …